Retatrutide vs Semaglutide vs Tirzepatide: Comparing GLP-1 Research Peptides
Semaglutide, tirzepatide and retatrutide activate one, two and three metabolic receptors respectively. Here is how their mechanisms differ and what each is studied for.
Semaglutide, tirzepatide and retatrutide are three incretin-pathway peptides studied extensively in metabolic research, and they form a clear mechanistic progression: semaglutide activates one receptor (GLP-1), tirzepatide activates two (GLP-1 and GIP), and retatrutide activates three (GLP-1, GIP and glucagon). Each additional receptor changes what the compound is studied for.
Semaglutide: Single-Receptor GLP-1 Agonist
Semaglutide is a modified GLP-1 analog carrying a C18 fatty-acid chain that binds reversibly to albumin, extending its half-life to roughly seven days. It engages GLP-1 receptors across the pancreas, hypothalamus and gastrointestinal tract, where it triggers glucose-dependent insulin secretion. The STEP-1 trial is the reference publication for this compound (Wilding et al., NEJM 2021). , NEJM 2021](https://pubmed.ncbi.nlm.nih.gov/33567185/)). A separate cardiovascular-outcomes trial (SUSTAIN-6) also reported reduced major adverse cardiovascular event risk in type 2 diabetes patients (Marso et al., NEJM 2016). Full detail on the semaglutide product page.
Tirzepatide: Dual GLP-1/GIP Agonist
Tirzepatide activates both the GLP-1 and GIP receptors from a single peptide. The GLP-1 component engages the same receptor as semaglutide, while the added GIP component sharpens insulin sensitivity in adipose tissue and amplifies glucose-dependent insulin secretion. The SURMOUNT-1 trial is the reference publication for this compound (Jastreboff et al., NEJM 2022)., NEJM 2021](https://pubmed.ncbi.nlm.nih.gov/34170647/)). Full detail on the tirzepatide product page.
Retatrutide: Triple GLP-1/GIP/Glucagon Agonist
Retatrutide (LY3437943) extends the mechanism one step further by adding glucagon receptor activation alongside GLP-1 and GIP. The GLP-1 and GIP arms function similarly to tirzepatide, while glucagon receptor activation adds a third signalling pathway in hepatic tissue. Because simultaneous GLP-1 activation offsets glucagon’s glucose-raising tendency, the Phase 2 programme is published in Jastreboff et al., NEJM 2023., NEJM 2023](https://pubmed.ncbi.nlm.nih.gov/37385285/)), alongside separate Phase 2 data in type 2 diabetes populations (Rosenstock et al., Lancet 2023). Full detail on the retatrutide product page.
Comparison Table
| Semaglutide | Tirzepatide | Retatrutide | |
|---|---|---|---|
| Receptors activated | GLP-1 | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| Half-life | ~7 days | ~5 days | ~6 days |
| Receptor targets | GLP-1 | GLP-1 + GIP | GLP-1 + GIP + glucagon |
| Reference publication | STEP-1 (NEJM 2021) | SURMOUNT-1 (NEJM 2022) | Phase 2 (NEJM 2023) |
| Additional studied pathway | Cardiovascular risk markers (SUSTAIN-6) | Comparative glycemic control (SURPASS-2) | Hepatic lipid metabolism, energy expenditure |
Why the Receptor Count Matters Mechanistically
Each added receptor engages a genuinely separate physiological lever, not a redundant one:
- GLP-1 acts primarily on appetite and gastric emptying
- GIP sharpens insulin sensitivity and influences adipose-tissue handling of nutrients
- Glucagon is the outlier - instead of reducing intake, it raises hepatic fatty-acid oxidation and resting energy expenditure
This is why retatrutide is studied as a genuinely distinct mechanism rather than simply a “stronger” version of tirzepatide: it is the only one of the three that acts meaningfully on the expenditure side of energy balance rather than only the intake side.
A Note on Head-to-Head Comparisons
No published trial has directly compared all three compounds against each other in the same study population. The percentages above come from separate trials with different designs, populations and durations, so they describe general mechanistic and trial-level trends rather than a controlled head-to-head ranking.
For the full GLP-1 and incretin-pathway lineup, including additional weight-management-focused compounds, see the Weight Management category.
Research Use Only
Semaglutide, tirzepatide and retatrutide as discussed here are supplied strictly for laboratory and research use, not for human administration. Nothing in this article constitutes medical advice, a dosing recommendation, or a claim of therapeutic outcome. All efficacy figures cited are drawn directly from the published trials linked above.
Interested in the peptides discussed in this article?
Browse our full catalog of research-grade peptides or contact us for personalized recommendations.